Theratechnologies was founded in 1993. Scientists at Theratechnologies discovered EGRIFTA® (tesamorelin for injection) in 1995. For the next fifteen years, Theratechnologies pursued the development of this innovative treatment for lipodystrophy in people living with HIV. In 2010, Theratechnologies received a marketing authorization for EGRIFTA® from the Food and Drug Administration in the United States.
World Point EN
Theratechnologies employs 40 people at its head office located at 2015 Peel Street, 11th floor, Montreal, Quebec H3A 1T8.
Theratechnologies European head office is located in Dublin, Ireland. Around ten people are working at this office located at 2 rue Hume Street, 4th floor, Dublin 2, D02 DV24.
Theratechnologies around the world
Theratechnologies operates in Canada, the United States and Europe.